• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccines (Basel) . Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets

tetano

Editor, Senior Moderator
Vaccines (Basel)


. 2022 Aug 11;10(8):1304.
doi: 10.3390/vaccines10081304.
Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets


Limin Zhang[SUP] 1 [/SUP], Junyu Chen[SUP] 2 [/SUP], Chenguang Shen[SUP] 3 [/SUP], Guosong Wang[SUP] 2 [/SUP], Zhen Lu[SUP] 2 [/SUP], Dian Zeng[SUP] 1 [/SUP], Ying Gao[SUP] 1 [/SUP], Huiqing Chen[SUP] 1 [/SUP], Ningshao Xia[SUP] 1 2 [/SUP], Yixin Chen[SUP] 1 2 [/SUP]



Affiliations

Abstract

Recent efforts have been directed toward the development of universal influenza vaccines inducing broadly neutralizing antibodies to conserved antigenic supersites of Hemagglutinin (HA). Although several studies raise the importance of glycosylation in HA antigen design, whether this theory can be widely confirmed remains unclear; which influenza HA with an altered glycosylation profile could impact the amplitude and focus of the host immune response. Here, we evaluated the characteristics and efficacy of deglycosylated modified HA proteins, including monoglycosylated HA (HA[SUB]mg[/SUB]), unglycosylated HA (HA[SUB]ug[/SUB]), and fully glycosylated HA (HA[SUB]fg[/SUB]), without treatment with H3N2 Wisconsin/67/2005. Our results showed that HA[SUB]ug[/SUB] could induce a cross-strain protective immune response in mice against both H3N2 and H7N9 subtypes with better antibody-dependent cellular cytotoxicity (ADCC) than the HA[SUB]mg[/SUB]- and HA[SUB]fg[/SUB]-immunized groups, which suggested that highly conserved epitopes that were masked by surface glycosylation may be exposed and thus promote the induction of broad antibodies that recognize the hidden epitopes. This strategy may also supplement the direction of deglycosylated modified HA for universal influenza vaccines.

Keywords: Hemagglutinin; deglycosylation modification; glycosylation; universal influenza vaccine.
 
Back
Top Bottom